Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Lenalidomide in Relapsed/Refractory CTCL
NCT03373305Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brentuximab vedotin and lenalidomide in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by City of Hope. Planned start Mar 2019; status: withdrawn.
02
Drugs
brentuximab vedotinlenalidomide
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT03373305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373305.